Science Explorer Back to mapMap
Discussion
Researcher · Institut Curie · France

Maud Kamal

Maud Kamal publishes mostly in Oncology, Cancer Research and Molecular Biology, on topics such as Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations and Cancer Immunotherapy and Biomarkers.

ORCID 0000-0003-1466-0950 OpenAlex
World rank
#310,412
of 7,710,434 ranked researchers
Rank in France
#17,893
of 324,115
Works
339
Citations
6.5k
Citations per work
19.1
h-index
40
i10-index 78Top 6.3% in Oncology
Maud Kamal

What does Maud Kamal research?

Maud Kamal's work is mostly in Medicine (37%), Biochemistry, Genetics and Molecular Biology (32%).

Health Sciences: 125 works · 37.0% of their workMedicine: 125 works · 37.0% of their workOncology: 55 works · 16.2% of their workPulmonary and Respiratory Medicine: 38 works · 11.2% of their workEpidemiology: 17 works · 5.0% of their workSurgery: 16 works · 4.6% of their workLife Sciences: 107 works · 31.5% of their workBiochemistry, Genetics and Molecular Biology: 107 works · 31.5% of their workCancer Research: 54 works · 16.0% of their workMolecular Biology: 53 works · 15.5% of their workEverything else: 107 works · 31.5% of their workTHEIR WORKMaud Kamal339works
Life Sciences32%Health Sciences37%

Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.

The fields and subfields, with their numbers
    1. Medicine12537.0%
    1. Biochemistry, Genetics and Molecular Biology10731.5%
  3. Everything else10731.5%
  1. 1Oncology16% of their works
  2. 2Cancer Research16% of their works
  3. 3Molecular Biology16% of their works
  4. 4Pulmonary and Respiratory Medicine11% of their works
  5. 5Epidemiology5% of their works
  6. 6Surgery5% of their works

Research topics

Which keywords describe Maud Kamal's research?

The keywords of their largest research topics: Targeted Therapy, Cancer Genomics, Mutational Signatures, ALK Inhibitors, EGFR Mutations, Precision Medicine, Cervical Cancer and Cetuximab.

Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.

All 22 words, with their numbers
  1. Targeted Therapy1312 topics
  2. Cancer Genomics851 topic
  3. Mutational Signatures851 topic
  4. ALK Inhibitors461 topic
  5. EGFR Mutations461 topic
  6. Precision Medicine402 topics
  7. Cervical Cancer392 topics
  8. Cetuximab392 topics
  9. Chemotherapy392 topics
  10. Human Papillomavirus352 topics
  11. Fluorouracil241 topic
  12. Immune Checkpoint Blockade241 topic
  13. KRAS Mutations241 topic
  14. PD-1 and PD-L1241 topic
  15. Epidemiology201 topic
  16. HPV Vaccination201 topic
  17. Brachytherapy191 topic
  18. Endometrial Carcinoma191 topic
  19. Medical Imaging161 topic
  20. Radiomics161 topic
  21. Oropharyngeal Cancer151 topic
  22. Radiotherapy151 topic

Where does Maud Kamal work?

Maud Kamal's main affiliation in the publication record is Institut Curie, France.

How many publications and citations does Maud Kamal have?

OpenAlex counts 339 works and 6,479 citations for Maud Kamal, an h-index of 40, ranking #310,412 of 7,710,434 researchers worldwide on the quality score.

Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.

Other researchers named Maud Kamal

Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.

Discussion

Ask a question or share a note about Maud Kamal. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.